Identification of Enolase 1 and Thrombospondin-1 as serum biomarkers in HBV hepatic fibrosis by proteomics

Proteome Science

Xueping Feng²  Jing Liu⁴  Xiaoqiong Wu⁵  Bin Deng³  Zi Wang⁴  Bin Zhang¹ 

[1] Department of Histology and Embryology, Xiangya School of Medicine, Central South University, 172 Tongzipo Road, Changsha, Hunan 410013, People’s Republic of China;Institute of Medical Sciences, Xiangya Hospital, Central South University, 87, Xiangya Road, Changsha, Hunan 410008, People’s Republic of China;Department of Cardiology, Xiangya Hospital, Central South University, 87, Xiangya Road, Changsha, Hunan 410008, People’s Republic of China;Molecular Biology Research Center, Xiangya School of Medicine, Central South University, 87, Xiangya Road, Changsha, Hunan 410008, People’s Republic of China;Department of Anatomy and Neurobiology, Xiangya School of Medicine, Central South University, 172 Tongzipo Road, Changsha, Hunan 410013, People’s Republic of China

关键词: TSP-1;    Enolase-1;    Biomarker;    HBV;    Serum proteomics;    Hepatic fibrosis;   

Others  :  816854
DOI  :  10.1186/1477-5956-11-30

 received in 2012-08-26, accepted in 2013-07-02,  发布年份 2013

【 摘 要 】

Hepatic fibrosis is an inevitable process in the progression of chronic HBV infection to hepatic cirrhosis, but its detailed mechanism is still unknown. Clinic serum biomarkers of HBV hepatic cirrhosis were scanned by proteomic methods. We used two-dimensional electrophoresis (2-DE) and Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF-MS) to separate and identify the proteins which were differentially expressed in the serum of patients with hepatic fibrosis compared to HBV carriers. We identified 27 differentially expressed proteins, of which 19 proteins were up-regulated and 8 proteins were down-regulated in the serum of patients with hepatic fibrosis compared to HBV carriers. The expression level of enolase-1 (α-enolase) was decreased while the level of thrombospondin-1 (TSP-1) increased in the serum of patients with hepatic fibrosis by western blot. Enolase-1 and TSP-1 may be useful as biomarkers for the clinic diagnosis of hepatic fibrosis, but further study is necessary.

【 授权许可】

   
2013 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Piao RL, Brigstock DR, et al.: Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis. World J Gastroenterol 2012, 18(18):2280-2286.
• [2]Sun HQ, Zhang JY, et al.: Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepat 2012, 19(6):396-403.
• [3]Becker L, Salameh W, Sferruzza A, et al.: Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol 2009, 7(6):696-701.
• [4]Germani G, Hytiroglou P, et al.: Assessment of fibrosis and cirrhosis in liver biopsies: an update. Semin Liver Dis 2011, 31(1):82-90.
• [5]Bioulac-Sage P: Primary biliary cirrhosis: a new histological staging and grading system proposed by Japanese authors. Clin Res Hepatol Gastroenterol 2011, 35(5):333-335.
• [6]Nakanuma Y, Zen Y, et al.: Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int 2010, 60(3):167-174.
• [7]Pham TV, Piersma SR, et al.: Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Rev Mol Diagn 2012, 12(4):343-359.
• [8]Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
• [9]Fontana RJ, Goodman ZD, et al.: Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008, 47(3):789-798.
• [10]Ray S, Reddy PJ, et al.: Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11(11):2139-2161.
• [11]Gerlt JA, Babbitt PC, et al.: Divergent evolution in enolase superfamily: strategies for assigning functions. J Biol Chem 2012, 287(1):29-34.
• [12]Butterfield DA, Lange ML: Multifunctional roles of enolase in Alzheimer’s disease brain: beyond altered glucose metabolism. J Neurochem 2009, 111(4):915-933.
• [13]Freeman WD, Chiota NA: Neuron-specific enolase correlates with other prognostic markers after cardiac arrest. Neurology 2011, 77(20):1856-1857.
• [14]Wygrecka M, Marsh LM, et al.: Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood 2009, 113(22):5588-5598.
• [15]Capello M, Ferri-Borgogno S, et al.: α-Enolase: a promising therapeutic and diagnostic tumor target. FEBS J 2011, 278(7):1064-1074.
• [16]Takashima M, Kuramitsu Y, et al.: Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma:association with tumor progression as determined by p roteomic analysis. Proteomics 2005, 5(6):1686-1692.
• [17]Jiang W, Li X, et al.: Constructing disease-specific gene networks using pair-wise relevance metric: application to colon cancer identifies interleukin 8, desmin and enolase 1 as the central elements. BMC Syst Biol 2008, 2:72.
• [18]Lawler PR, Lawler J: Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2012, 2(5):a006627.
• [19]Wight TN, Raugi GJ, et al.: Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem 1985, 33(4):295-302.
• [20]Naganuma H, Satoh E, et al.: Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells. J Neurooncol 2004, 70(3):309-317.
• [21]McGregor B, Colon S, et al.: Thrombospondin in human glomerulopathies. A marker of inflammation and early fibrosis. Am J Pathol 1994, 144(6):1281-1287.
• [22]Ioachim E, Damala K, et al.: Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. Histol Histopathol 2012, 27(2):209-216.
• [23]Rojas A, Meherem S, et al.: The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. Int J Cancer 2008, 123(1):14-21.
• [24]Daniel C, Wiede J, et al.: Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 2004, 65(2):459-468.
• [25]Presser LD, Haskett A, et al.: Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-β1: role of TGF-β1 in HCV replication. Virology 2011, 412(2):284-296.
• [26]Frangogiannis NG, Ren G, et al.: Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 2005, 111(22):2935-2942.
• [27]Elpek GO, Gokhan GA, et al.: Thrombospondin-1 expression correlates with angiogenesis in experimental cirrhosis. World J Gastroenterol 2008, 14(14):2213-2217.
• [28]Johnson RF, Perkins ND: Nuclear factor-κB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends Biochem Sci 2012, 37(8):317-324.
• [29]Nelius T, Filleur S, et al.: Androgen receptor targets NfkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 2007, 121(5):999-1008.
• [30]El-Youssef M, Mu Y, et al.: Increased expression of transforming growth factor-beta1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell. J Pediatr Gastroenterol Nutr 1999, 28(4):386-392.